Yu Yu, Wong Jacky, Lovejoy David B, Kalinowski Danuta S, Richardson Des R
Iron Metabolism and Chelation Program, Department of Pathology, University of Sydney, Sydney, New South Wales, Australia.
Clin Cancer Res. 2006 Dec 1;12(23):6876-83. doi: 10.1158/1078-0432.CCR-06-1954.
The importance of iron and copper in cancer biology has been well established. Iron plays a fundamental role in cellular proliferation and copper has been shown to be a significant cofactor for angiogenesis. Early observations with the chelator used for the treatment of iron overload, desferrioxamine, showed that it had promise as an anticancer agent. These results sparked great interest in the possibility of developing more effective iron chelators for cancer therapy. The recent entry into clinical trials of the iron-binding drug, Triapine, provides evidence of the potential of this antitumor strategy. Likewise, chelators originally designed to treat disorders of copper overload, such as penicillamine, trientine, and tetrathiomolybdate, have also emerged as potential anticancer drugs, as they are able to target the key angiogenic cofactor, copper. In this review, we will discuss the development of these and other chelators that show potential as anticancer agents.
铁和铜在癌症生物学中的重要性已得到充分证实。铁在细胞增殖中起着基础性作用，而铜已被证明是血管生成的重要辅助因子。早期使用用于治疗铁过载的螯合剂去铁胺的观察结果表明，它有望成为一种抗癌药物。这些结果引发了人们对开发更有效的用于癌症治疗的铁螯合剂可能性的极大兴趣。铁结合药物曲拉滨最近进入临床试验，为这种抗肿瘤策略的潜力提供了证据。同样，最初设计用于治疗铜过载疾病的螯合剂，如青霉胺、曲恩汀和四硫钼酸盐，也已成为潜在的抗癌药物，因为它们能够靶向关键的血管生成辅助因子铜。在这篇综述中，我们将讨论这些以及其他显示出作为抗癌药物潜力的螯合剂的发展情况。
